This unbiased approach allowed them to discover previously unknown methylation events that affect protein levels and drive cancer. One finding in particular caught Ding’s attention. Hypomethylation on ...

At the moment, FGFR2 and FGFR3 inhibitor Balversa is only FDA-approved for bladder cancer. Around 25,000 people in Japan are diagnosed with biliary tract cancer, with a five-year survival rate of ...

Hutchmed has concluded enrolment of its multi-centre Phase II trial of fanregratinib (HMPL-453), a treatment for intrahepatic ...

Scientists believe that too much 2-HG can fuel the growth of bile duct cancer. Two other targeted therapies, pemigatinib (INCB054828) and infigratinib (BGJ398) help reduce the production of the ...

ovarian cancer and lung adenocarcinoma. However, developing highly selective FGFR2/3 inhibitors and overcoming drug resistance remain two of the most significant challenges in the field.

Genescience Pharmaceuticals Co. Ltd. has prepared and tested new fibroblast growth factor receptor 2 (FGFR2) and/or FGFR3 inhibitors reported to be useful for the treatment of cancer, ...

ovarian cancer and lung adenocarcinoma. However, developing highly selective FGFR2/3 inhibitors and overcoming drug resistance remain two of the most significant challenges in the field.

About IHCC with FGFR2 Fusion/Rearrangement IHCC is one of the subtypes of primary bile duct cancer. In China, an estimated 61,900 newly diagnosed IHCC occurred in 2015 and the overall IHCC ...

FGFR2 is not the focus now, and all eyes are on proving the value of its PI3Kα program. Interim data for RLY-2608, presented at the San Antonio Breast Cancer Symposium, reinforced its potential ...

Colorectal cancer (CRC) presents a significant health ... ALK, ROS1, NTRKs, RET, FGFR2, and EGFR. These genetic alterations ...

BALVERSA (erdafitinib) has strong market potential in the FGFR-altered urothelial carcinoma space, particularly as a targeted therapy for patients with FGFR2/3 mutations. With the growing emphasis on ...